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Beyond ABC: Another Mechanism of
Drug Resistance in Melanoma Side
Population
Mizuho Fukunaga-Kalabis1 and Meenhard Herlyn1
It has been shown that a side population (SP), which is characterized by high
chemical efflux capacity, is present in human melanoma cell lines. However, it
was not clear whether patients’ samples contain the same subpopulation. In this
issue, Luo et al. (2012) report that they have isolated SP cells directly from patients’
melanomas. SP cells are resistant to paclitaxel because of the upregulation of
ABCB1 and ABCB5. Notably, these cells are also resistant to temozolomide, which
is not a substrate for ATP-Binding Cassette (ABC) transporters, in an interleukin
(IL)-8-dependent manner. This study provides novel clues for understanding how
a small, but critical, subpopulation within melanomas is resistant to therapies.
The Journal of Investigative Dermatology (2012) 132, 2317–2319. doi:10.1038/jid.2012.220
Melanomas are often resistant to
pharmacological therapies. Conventional
chemotherapy drugs currently used in
clinics are of limited value in treating
advanced melanomas. Tumor shrinkage
induced by these drugs is often tempor-
ary, and most tumors progress or relapse
after short periods of time. Both intrin-
sic and acquired mechanisms have roles
in the chemoresistance of melanoma
cells. One of the key properties for intrin-
sic resistance is the expression of certain
ABC superfamily proteins, which function
as ATP-dependent efflux transporters. The
ABC family comprises nearly 50 members
that are evolutionary highly conserved
and have high sequence homology among
its members. These transporters regu-
late tissue protection against endogenous
and exogenous cellular toxins. Some of
the ABC transporters are expressed ubiqui-
tously among diverse cancer cell lines
(NCI-60), whereas others are expressed
selectively in cancer cells derived from
particular tissue types (Szakacs et al.,
2004). Melanoma cells express a group
of ABC transporters, including ABCA9,
ABCB1, ABCB5, ABCB8, ABCC2, and
ABCD1 (Chen et al., 2009). Although it
has been reported that ABCB5 and ABCB8
See related article on pg 2440
1Tumormicroenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania, USA
Correspondence: Meenhard Herlyn, Tumormicroenvironment and Metastasis Program, The Wistar
Institute, 3601 Spruce Street, Philadelphia, Pennsylvania 19104, USA. E-mail: herlynm@wistar.org
COMMENTARY
www.jidonline.org 2317
mediate doxorubicin resistance in mela-
noma cells (Frank et al., 2005; Elliott and
Al-Hajj, 2009), and ABCC2 expression is
associated with cisplatin resistance (Liedert
et al., 2003), the physiological functions of
most ABC transporters in melanomas have
not been elucidated.
The Hoechst 33342 dye exclusion assay
is broadly performed to analyze the efflux
capacity of cells. When Hoechst 33342 is
excited by a UV laser, the dye emits blue
(450nm) and red (675nm) wavelengths.
A gradient of fluorescence of the dye
monitored by flow cytometry at both
wavelengths is usually seen as a comma-
like region on an x–y plot. The tip of the
comma-like region forms a tail, which
displays low blue and red fluorescence.
This subpopulation, termed ‘side popula-
tion’, has high efflux capacity and has
been identified in several tissues of mam-
malian species (Goodell et al., 1996).
Likely, the increased efflux capacity of
the SP is promoted through ABC transpor-
ters. Most commonly, ABCB1 and ABCG2
are highly expressed in SPs of many tissue
types and are responsible for transporting
Hoechst 33342, as well as chemothera-
peutic drugs; vinblastin and paclitaxel are
expelled by ABCB1, whereas topotecan
and methotrexate are the substrates of
ABCG2 (Hadnagy et al., 2006).
The SP assay initially attracted attention
among stem cell researchers as a strategy to
isolate potential stem/progenitor cells from
various tissues, because cell surface mar-
kers for stem cells are still not defined in
many organ systems. More recently, the
assay has been used with cell lines and
patient-derived tumor material from various
types of cancer to identify cells that exhibit
stem cell–like properties. Several groups
have characterized SP cells in melanoma
(Grichnik et al., 2006; Fukunaga-Kalabis
et al., 2010; Roesch et al., 2010; Wouters
et al., 2012). Melanoma SPs from cell lines
are small in size (Grichnik et al., 2006),
slow growing (Grichnik et al., 2006;
Roesch et al., 2010), and, most import-
antly, resistant to chemotherapy (Fukunaga-
Kalabis et al., 2010; Wouters et al., 2012).
Although these studies with cell lines sug-
gest that melanomas contain a subpopula-
tion intrinsically resistant to chemothera-
peutic drugs, it remains unclear whether
the SP phenotype is clinically relevant or
more of a culture artifact.
In this issue, Luo et al. (2012) report
that patients’ melanomas indeed do
contain an SP. They performed the
Hoechst assay on suspensions of mela-
noma cells, which were directly isolated
from tumor tissues and patient-derived
tumor xenografts (PDX model). Original
tumors showed the presence of SP cells
ranging from 0.1 to 0.7%, regardless
of whether the lesions were primary or
metastatic. Melanoma cell lines from
previous and the current studies showed
a heightened fraction of SP cells, close to
10% of the total population. It is likely that
in vitro culture systems provide a selec-
tive pressure for the expansion of speci-
fic tumor subpopulations. PDX tumors
showed a similar percentage of SP cells
compared with their original tumor,
indicating that this in vivo model has the
significant advantage of maintaining the
heterogeneity of the tumors of origin. Both
paclitaxel and temozolomide treatment,
the former is the substrate of ABCB1 and
the latter is not, increased the ratio of
SP cells in the remaining tumors of PDX
mice, suggesting that SP cells in mela-
noma are resistant to chemotherapy
in vivo. Melanoma SP cells showed
higher expression of multiple ABC trans-
porters, including ABCB1 and ABCB5,
compared with the non-SP fraction.
When these two ABC members were
knocked down in a melanoma cell
line, the percentage of the SP was signi-
ficantly decreased, and the cells regained
sensitivity to paclitaxel. Knocking down
neither ABCB1 nor ABCB5 affected the
response to temozolomide in mela-
noma. The authors further explored the
mechanism responsible for temozolo-
mide resistance of SP cells. The patient-
derived SP cells highly expressed IL-8,
which has been suggested to be asso-
ciated with chemoresistance in mela-
noma cells. Blocking IL-8 signaling with
neutralizing antibodies or small inter-
fering RNA significantly increased sensi-
tivity to temozolomide in vitro (the
former specifically decreased the resis-
tance in a SP). Moreover, microarray
data revealed that SP cells are enriched
with components of the inflammatory
response, especially in the NF-kB
signaling pathway, which may contri-
bute to chemoresistance in an ABC
transporter–independent manner. These
findings suggest that not only efflux capa-
city, but also other intrinsic mechanisms
confer the resistance of melanoma SP
cells against multiple drugs, which are
not substrates for ABC transporters.
Further studies are warranted to deter-
mine whether the inhibition of IL-8 or
NF-kB signaling can reverse drug resis-
tance of melanoma cells in vivo. Such
studies will contribute to progress in the
therapy of this tumor, which remains
challenging to treat.
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